Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.47 |
| ▸ | BCR | P11274 | 6/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536534 | 0.87 | LMNA (0.48) | AURKAHPGDLMNAKDM4EALDH1A1 | |
| SCHEMBL3533772 | 0.84 | KDM4E (0.45) | AURKALMNAKDM4EALDH1A1 | |
| SCHEMBL3535327 | 0.83 | AURKA (0.58) | AURKAMAPK8MAPK10KDM4EALDH1A1 | |
| SCHEMBL3527049 | 0.82 | AURKA (0.68) | AURKAKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3535511 | 0.78 | AURKA (0.49) | AURKA | |
| SCHEMBL3537132 | 0.78 | AURKA (0.54) | AURKA | |
| SCHEMBL3531365 | 0.78 | AURKA (0.51) | AURKAKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3529803 | 0.77 | AURKA (0.51) | AURKALMNAKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3533123 | 0.74 | PTGDR2 (0.40) | AURKAPTGDR2 | |
| Trifluoroacetic Acid SCHEMBL3532665 | 0.74 | GPR6 (0.38) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813609-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | MSD KK (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7834018-B2 | aurora kinase inhibitors; 2-(thiazol-2-ylamino)pyridine compounds as antitumor agents; 6-((4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl)-N-thiazol-2-ylpyridin-2-amine for example | BANYU PHARMACEUTICAL CO., LTD (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-7491720-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| CN-101103017-A | Novel aminopyridine derivatives having Aurora-A selective inhibitory action | BANYU PHARMA CO LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | AURKA, AURKC, AURKB | ABL1 163/4885BCR 880/4885AURKA 1/4885 |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | ABL1 163/4885BCR 880/4885AURKA 1/4885 |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | ABL1 163/4885BCR 880/4885AURKA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.